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Abstract
Multifocal and recurrent epithelial tumors, originating from either dormant or de novo cancer
cells, are major causes of morbidity and mortality. The age-dependent increase of cancer incidence
has long been assumed to result from the sequential accumulation of cancer driving or facilitating
mutations with induction of cellular senescence as a protective mechanism. However, recent
evidence suggests that the initiation and development of epithelial cancer results from a close
interplay with its altered tissue microenvironment, with chronic inflammation, stromal senescence,
autophagy, and activation of cancer associated fibroblasts (CAFs) playing possible primary roles.
We will discuss recent progress in these areas, and highlight how this understanding may be used
for devising novel preventive and therapeutic approaches to the epithelial cancer problem.
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Drivers of epithelial carcinogenesis
The accumulation of genetic and epigenetic changes in target cells is commonly viewed as
the primary cause of epithelial cancer development. However, the analysis of surgically
excised non-tumor areas as well as the increased use of non-invasive imaging techniques has
revealed a surprisingly high incidence of precancerous epithelial lesions, which might never
progress into malignancy [1, 2]. Many genetic mutations implicated as "drivers" of the
carcinogenic process can be found in these lesions, bringing into question whether such
changes are of primary causative significance for cancer outgrowths [3]. Also, for reasons
that are not understood, epithelial cancers of various types are often multifocal, with
secondary primary tumors frequently developing at a significant distance from the primary
tumors [4].
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Substantial evidence suggests that development of epithelial neoplastic lesions involves
alterations of a normal stromal environment. The stromal environment consists of several
cell types (BOX1), which can often become dysregulated due to aging, environmental
changes, and inflammation. As discussed further below, fibroblasts can become senescent
through aging and environmental stress and these senescent fibroblasts can contribute to a
tumor permissive environment by secreting specific cytokines, growth factors and
metalloproteases, which constitute the Senescence Associated Secretory Phenotype (SASP)
[5, 6]. Furthermore, as cancer has often been classified as a “wound that never heals” [7],
similarities exist between the stromal microenvironment during wound healing and cancer
progression [8] (Box 2). Similar to wound healing, resident fibroblasts in a tumor
microenvironment convert into contractile myofibroblasts termed cancer associated
fibroblasts (CAFs) [9], which are capable of enhancing tumorigenic behavior of neighboring
cells [9, 10]. In addition, recent studies show that there is a close association between the
lysosomal degradative process known as autophagy and the tumor microenvironment. Both
CAFs and senescent cells display altered autophagy, which can fuel and mold the stromal
environment [6, 11] leading to tumor progression.
The contribution of stromal alterations to cancer progression and metastasis has been
covered by excellent reviews (see for instance [9, 10, 12]). Here we intend to provide
selective highlights on how stromal changes caused by chronic inflammation and activation
of cancer associated fibroblasts, in association with stromal cell senescence and/or increased
autophagy, may contribute to initiation of epithelial carcinogenesis. We will further discuss
how this knowledge may be used for development of novel preventive and therapeutic
approaches to epithelial tumors, including multifocal and recurrent forms.
Stromal tissue inflammation and epithelial cancer
Chronic inflammation plays an important role in cancer initiation. For instance, patients with
ulcerative colitis have an increased incidence of colon cancer. Similarly, mice administered
dextran sodium sulfate (DSS), a pro-inflammatory tissue-damaging agent devoid of
mutagenic activity, form colon cancer [13]. In addition, inflammation due to Helicobacter
pilori infection may also be a likely mediator of stomach cancer development [14].
In both normal and cancer settings, inflammation involves a complex orchestration of cells
of the innate and acquired immune systems. Neutrophils are the first cells recruited to sites
of acute inflammation [15]. Production of interleukin 6 (IL6) and macrophage colony
stimulating factor 1 (CSF-1) by these cells or by the incipient cancer cells can push myeloid
precursors towards the macrophage lineage [16]. Macrophages play a key role as both
suppressors and enhancers of carcinogenesis [17]. These cells are very dynamic and can
assume a “killing” M1 phenotype, for elimination of pathogens and cancer cells, or a
permissive M2 phenotype, for resolution or containment of acute inflammation [18].
Notably, within chronic inflammatory stroma both M1 and M2 macrophage populations
coexist and most macrophages can possess a mixed phenotype [19]
Macrophages can also regulate the inflammatory microenvironment by generating reactive
oxygen species (ROS), reactive nitrogen species (RNS) and prostaglandins, of which their
synthesis is the target of many pharmacological approaches (TABLE 1) [20]. Indeed,
genetic and pharmacologic suppression of the enzyme Cyclooxygenase 2 (COX2), which is
responsible for prostaglandin production, can significantly delay cancer development in a
number of experimental and clinical settings. Inhibition of the COX2-dependent pathway
suppresses both tumor-associated angiogenesis and tumor growth in mice [21, 22], and mice
lacking COX2 are resistant to colorectal cancer development [6, 23, 24]. In humans,
epidemiological studies have shown that COX2 inhibitors can reduce the risk of several
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types of cancer [22]. It is believed that inflammation can increase chromosomal instability
through the production of ROS and RNS, thus linking inflammation to cancer initiation (Fig.
1) [25].
The suppression of cancer-promoting chronic inflammation, by itself or coupled with
induction of a transient acute inflammatory reaction, provides a promising approach for
prevention and treatment of early phases of epithelial cancer [20, 26]. Such intervention
modalities are already employed in the skin, in which development of actinic keratosis, a
very common precursor of cutaneous squamous cell carcinoma (SCC), is intimately
connected with UV light-induced chronic inflammation [27]. These lesions can be
effectively prevented by counteracting the UV light effects with agonists of Toll Like
Receptors (TLRs) producing a potent acute inflammatory reaction [28]. Thus, an approach
aimed to reeducate or redirect the inflammatory response may represent a powerful
preventive and therapeutic tool, at least in some cancer settings.
Alterations of mesenchymal stromal cells as primary determinants of
epithelial cancer
Substantial evidence supports the notion that cancer progression and metastasis are the result
of co-evolving alterations in cancer cells and cells of the surrounding stroma [29–31]. While
epigenetic events are an accepted mechanism for changes in in the tumor-surrounding
stroma, chromosomal and/or genetic alterations, including loss of p53, have also been
reported [32–36], although the general significance of these findings is unclear [31].
Together or preceding inflammation, several lines of evidence discussed below indicate that
mesenchymal stromal alterations can also be a trigger for initiation of epithelial cancer.
A number of genetic, human syndromes with intrinsic deregulation of stromal cells result in
benign outgrowths and secondary high risk of epithelial cancer, as previously reviewed [37].
For example, patients with Peutz-Jeghers Syndrome (PJS) develop hamartomatous polyps
primarily in the intestine, but also at several other sites, and have an increased risk of
developing epithelial colon cancer [37]. At the basis of PJS is the germ-line transmission of
inactivating mutations of the liver kinase B1 (LKB-1) gene [38]. LKB-1 is best known for
controlling 5' AMP-activated protein kinase (AMPK) signaling with a consequent impact on
mTOR activity, cellular metabolism and protein synthesis [39]. However, the role of LKB-1
in the colonic mesenchyme has been connected to a different mechanism, involving
decreased expression of transforming growth factor β (TGF-β) and consequently impaired
myofibroblast differentiation [40]. This in turn may lead to hamartomatous
hyperproliferation with secondary increased inflammation and risk of epithelial cancer
development.
Other lines of work, based on mouse genetic models, point to the importance of stromal
alterations that directly affect adjacent epithelia leading to epithelial dysplasia and neoplasia
rather than mesenchymal outgrowths. Recent evidence suggests that activation of TGF-β
signaling in the fibroblast can exert a pro-tumorigenic role on adjacent epithelium. TGF-β, a
key regulator of stromal fibroblast function, can induce both fibrosis and CAF activation
[10, 41, 42]. TGF-β signals downstream via activation of the TGF-β receptor by first binding
the TGF-β type II receptor (Tgfr2) and recruiting the TGF-β type I receptor (Tgfr1) [43].
Thus, to assess the role of this pathway in the mesenchymal compartment, mice with
fibroblast-specific ablation of the Tgfr2 gene were studied [44]. Epithelial cancerous or
precancerous lesions consistently developed in the forestomach and prostate of these mice,
with increased proliferation of surrounding fibroblasts [44]. As a possible paracrine
mechanism, loss of Tgfr2 specifically in gastric and prostate fibroblasts up-regulated the
expression of known epithelial growth promoting factors, such as hepatocyte growth factor
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and Wnt [45, 46], and induced a cancer-promoting inflammatory reaction [47]. Importantly,
these findings are of likely clinical significance as decreased Tgfr2 expression has been
observed in the stroma of esophageal squamous cell carcinomas (SCCs) (equivalent to
mouse forestomach SCC) [48] as well as in prostate carcinomas [46, 49].
In addition to TFG-β, Notch signaling in the mesenchyme can also modulate the oncogenic
potential of adjacent epithelia. Unlike TGF-β, which signals at a distance, Notch signaling is
an important form of direct cell to cell communication with a key role in tissue development
and homeostasis [50]. Upon activation, the proteolytically cleaved Notch intracellular
domain associates with the DNA binding protein CSL, converting it from a transcriptional
repressor into an activator [51]. In the epidermal compartment of the skin, the Notch/CSL
pathway plays a key role in promoting keratinocyte differentiation and suppressing tumor
formation [52]. Loss of the CSL gene in the mesenchymal compartment was also found to
cause a skin phenotype with key features of field cancerization, including early and
widespread dermal atrophy, followed by expanding areas of inflammation and, as the mice
aged, multifocal keratinocyte tumors with features of actinic keratosis or in situ SCCs [53].
All mice developed multiple skin tumors, which were significantly counteracted by
pharmacological inhibition of inflammation. In both mouse and human dermal fibroblasts,
CSL loss resulted in the activation of a CAF-like phenotype, including growth factor up-
regulation, pro-inflammatory cytokine and matrix metalloprotease production. Importantly,
this stromal cell phenotype overlapped with the stroma phenotype seen in patients with
cutaneous field cancerization [53].
Taken together this evidence indicates that the stromal compartment can be a primary
determinant and important target for prevention and treatment of early stages of epithelial
cancer. Besides stromal inflammation, there is the attractive possibility of intervening on
other important stromal processes discussed below.
Stromal cell senescence and the senescence associated secretory
phenotype
Cellular senescence is a terminal cell fate characterized by an irreversible withdrawal from
the cell cycle. In vivo, senescent cells accumulate with age and senescence-related events are
thought to be a key driver of tissue aging [54]. During transformation, cells need to
overcome oncogene-induced senescence (OIS) as an intrinsic fail safe mechanism to prevent
tumor development [55]. However, senescent cells have also been implicated in regulating
cancer initiation and progression through modulation of neighboring cells [55].
Senescence can result from intrinsic, time-dependent, shortening of telomeres, from
inappropriate mitogenic stimulation (as in OIS), accumulation of genomic or mitochondrial
DNA mutations, or other degenerative events, such as protein glycosylation and lipid
oxidation [55–57]. Senescence can also be triggered by a variety of exogenous insults and
chronic stress, including UV exposure, gamma-irradiation, smoke-derived compounds and
other toxic chemicals, which may lead to cancer (Figure 1). For instance, UVA exposure
results in ROS production that can affect both epidermal and dermal compartments leading
to skin cancer [58]. Similarly, smoking can lead to an increased risk of cancer in the lungs,
and other organs such as the oral mucosa, bladder, liver, kidney, prostate and breast [59–
61]. Besides the epithelium, a recent report has suggested that smoke-derived chemicals can
target resident stromal fibroblasts, causing metabolic changes, DNA damage and accelerated
senescence [62].
Pro-senescence signals converge on either the p53 or p105Rb tumor suppressor pathways,
with p16 (ink4a) and p21Waf1/Cip1 [63], or miRNA 34 [64] and lncRNA p21 [65] as
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effectors. Senescent cells also undergo extensive chromatin remodeling resulting in drastic
changes in gene expression [66]. An important consequence of senescence is the acquisition
of a SASP [5]. SASP factors are potent tools by which senescent cells modify the tissue
microenvironment [5, 67]. They can be divided into three categories: 1) soluble signaling
factors (interleukins (IL), chemokines, and growth factors) 2) secreted proteases, and 3)
extracellular matrix components. The most prominent cytokines of the SASP are represented
by IL-1, IL-6, IL-8, Granulocyte-macrophage colony-stimulating factor (GM-CSF),
granulocyte-colony stimulating factor (G-CSF), interferons, TGF-β, insulin growth factor-
binding proteins (IGFBPs) and their regulators (IGFBP-rP1 and IGFBP-rP2, or connective
tissue growth factor—CTGF) [67, 68]. Several matrix metalloproteinases (MMPs) are also
produced by human and mouse fibroblasts undergoing replicative or stress-induced
senescence, including MMP-1 and MMP-3 [5]. Another family of proteases released by
senescent cells are serine proteases of the plasminogen activation pathway, urokinase- or
tissue-type plasminogen activators (uPA or tPA), which can trigger a mitogenic signal in
neighboring cells [69]. Senescent fibroblasts can also modulate the behavior of neighboring
cells through a more indirect mechanism, involving production of extracellular matrix
proteins like collagen and fibronectin [70, 71].
The SASP has been shown to reinforce senescence of normal epithelial cells and suppress
early epithelial transformation [5]. However, emerging evidence suggests senescence of
stromal cells can result in their acquisition of a CAF-like phenotype, resulting in the
capability of enhancing tumor formation in neighboring epithelial cells [5, 67, 68]. In the
breast, premalignant epithelial cells are induced to proliferate by stromal cells that have
undergone senescence spontaneously or upon irradiation [72–74] Similarly, in the oral
cavity, tobacco-driven senescence of stromal cells stimulates the growth of epithelial cells
with loss of epithelial integrity and altered differentiation [75]. In the prostate, senescent
fibroblasts can create a local tissue environment that favors epithelial cell hyper-
proliferation [76]. In addition, neighboring senescent stromal cells also induces epithelial-to-
mesenchymal transition (EMT) in surrounding epithelia [77]. Besides being an important
switch that enables cancer cells to migrate and invade [10], EMT was recently linked to the
control of cancer stem cell potential [78], suggesting that senescence-induced EMT could be
a very early event in the carcinogenic process.
Although the molecular mechanisms linking stromal cell senescence and SASP activation
remain to be elucidated, initial studies indicated that persistent DNA damage could be one
means of inducing the SASP [79]. However, persistent DNA damage induced by irradiation
or oncogenic RAS, was found to be sufficient, but not essential, for the induction of the
SASP [80] suggesting that an alternative mechanism independent of DNA damage may also
be involved. Consistent with this possibility, fibroblast senescence and SASP was found to
be induced by activation of the stress-inducible kinase p38 MAPK independent of DNA
damage [81].
Notably, recent evidence indicates that senescence is not necessarily linked to the induction
of a SASP. In fact, increased expression of p16 or p21 in human fibroblasts was reported to
induce senescence without establishing nor maintaining the SASP [80]. Furthermore, p16
may play an indirect role in repressing the SASP and SASP-dependent effects on epithelial
cells [80]. The possibility of dissociating stromal cell senescence from SASP is of great
potential therapeutic significance for approaches aiming to selectively interfere or block
these processes.
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Transcriptional regulators of stromal senescence and cancer-initiating
microenvironment
By virtue of their pleiotropic actions, transcription factors have long been considered master
regulators of the cellular microenvironment and represent possible targets for intervention.
A number of excellent reviews exist on the topic (see, for instance, [10, 20]); therefore, we
will only consider a few that have been closely implicated in control of the stromal cell
stress response and aging, including the AP1 family, nuclear factor kappa beta (NF-κB), and
Nuclear Factor erythroid 2-Related Factor 2 (NRF2).
Transcription factors of the AP1 family (Jun, Fos and ATF) are activated in response to a
number of mitogenic and stress derived signals [82, 83]. These factors are master regulators
of a large number of SASP genes and, for example, in the skin, are likely to play a key role
in chronic inflammation and photo-aging [84]. Indeed, strong evidence indicates that UV-
damage is linked to changes in gene expression in the dermal fibroblast compartment by
AP-1-regulated MMPs, including MMP-1, MMP-3 and MMP-9 [85]. Seminal studies on
mesenchymal-epithelial crosstalk involving AP1 family members were performed by
organotypic co-cultures of fibroblasts from Jun −/− and JunB −/− mice with primary human
keratinocytes. Loss of mesenchymal Jun resulted in decreased keratinocyte proliferation and
differentiation, and was associated with the loss of keratinocyte growth factor (KGF) and
GM-CSF expression by fibroblasts. By contrast, Jun B was found to suppress both of these
cytokines, and accordingly JunB −/− fibroblasts expressed constitutively high levels of both
KGF and GM-CSF, resulting in proliferation and differentiation of overlaying keratinocytes
[86, 87]. These findings outline the existence of a mesenchymal-epithelial paracrine
signaling loop regulated by the relative abundance of specific AP1 members within the
stroma and unveil the presence, within the AP1 family, of an antagonistic mechanism
regulating the same target genes, and thus tissue/organ homeostasis. Consistent with this
notion, AP-1 up-regulation may partly explain the CAF phenotype and resulting
keratinocyte tumor formation caused by loss of Notch/CSL signaling in skin fibroblasts [53].
In addition to AP-1, the transcription factor NF-κB plays a crucial role in inflammation and
in establishing a tumor promoting microenvironment [88]. NF-kb primarily controls pro-
inflammatory genes and enzymes, of which many are implicated in the SASP, and pro-
survival genes such as Bcl-XL [88, 89]. Studies in human mammary fibroblasts and
keratinocytes as well as systemic approaches aiming to identify promoters regulating age-
related genes across species and tissue have suggested a function for NF-κB [90] [91] [92].
In both human and mice, NF-κB was found to regulate age-associated gene expression
programs in vitro, while in vivo its DNA binding activity was found to increase with age in
several mouse tissues including skin, liver, heart and spleen [93]. More importantly, a
dominant-negative NF-κB mutant was able to revert both age-related phenotypes and the
age-dependent gene signature in skin [93]. These findings suggest that pharmacological
approaches to inhibit NF-κB signaling, directly or through suppression of inflammatory
signals, may serve to reverse age-related changes and associated detrimental effects.
The transcription factor NRF2 is part of a sensor system to detect cellular oxidative stress,
and is important for protection of epithelial and stromal tissues from UV irradiation and
toxic chemicals, cancer and, possibly, aging [94]. When relieved from inhibition by the
kelch-like ECH associated protein 1 (KEAP1), NRF2 upregulates important components of
the antioxidant response, including peroxiredoxin 1 and 6 [95]. Given the key role of ROS in
cellular DNA and protein damage, compromised NRF2 function could accelerate stromal
senescence and aging, and approaches aimed to increase NRF2 activity have been shown to
be beneficial [94, 96, 97]. However, NRF2 mutations associated with higher levels of
expression have been linked to specific cancer types, including SSC of the esophagus, skin,
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lung and larynx [94]. In fact, while initially cytoprotective, NRF2 accumulation can promote
tumor formation by excessive stress protection [94]. This double role is exemplified by
fumarate, a Krebs metabolite known to inhibit chemical carcinogenesis in mouse skin, lung
and liver [98, 99]. Recently fumarate has been shown to target KEAP, thus leading to NRF2
activation and providing a mechanism for its anti inflammatory therapeutic use. However, in
vivo loss of fumarate processing by fumarate hydratase resulted in fumarate accumulation
and chronic NRF2 activation, suggesting NRF2 is a possible cause of renal carcinoma [100].
Recent findings have also implicated NRF2 in promoting colon cancer, as its silencing in
cancer cells blocks hypoxia inducible factor (HIF1α) accumulation and suppresses both
tumor growth and angiogenesis [101]. Therefore, tissue-specific approaches for drug
delivery or action should be considered when targeting Nrf2.
Overall, there are many molecular targets regulating the stromal microenvironment and a
growing number of drugs are being used to modulate these targets (Figure 2 and TABLE 1).
Rather than focusing on molecules with single modes of action, it is likely that targeting the
pleiotropic gene network regulated by transcription factors might represent an efficient
approach for senescence modulation and/or cancer prevention.
Autophagy in control of tissue aging, stromal cell senescence and cancer
Autophagy (self-eating) is a cellular lysosomal degradative process, which maintains energy
metabolism and eliminates aged and damaged components, including proteins and
organelles [102]. A close association exists between senescence and autophagy; depending
on cellular and tissue contexts, autophagy can both trigger senescence and counteract it
[103, 104]. In addition, mitigation of tissue aging and associated cellular damage through
autophagy is considered a novel mechanism of tumor suppression, while inability to
eliminate cellular debris (defective autophagy) can create a damaging environment
predisposing cells to chronic inflammation and tumor initiation [11, 105]. The conditional
ablation of autophagy regulating genes, like beclin1 or atg7 in the liver and atg16L1 or atg5
in the colon, causes persistence of altered mitochondria and other organelles resulting in cell
and tissue dysfunction [11]. This damage is mediated, at least in part, by the deregulated
turnover of protein p62 [11], which is an adaptor that regulates various signal transduction
pathways. By sequestering KEAP1, p62 controls the levels of stress-responsive NRF2
resulting in an increased production of detoxifying enzymes [106]. Another consequence of
deregulated p62 levels results from its direct interaction with TRAF6 and the consequent
activation of the NF-κB pro-inflammatory cascade [107].
Thus autophagy can be highly beneficial in preventing and removing age-dependent tissue
and cellular damage leading to degeneration and, eventually, cancer. Autophagy however
can also play an important pro-senescence function. Oncogene induced senescence in
fibroblasts was reported to depend on autophagy [108]. In this system, senescence and
expression of two SASP cytokines, IL-6 and IL-8, were delayed by silencing of autophagy-
essential genes (atg5 or atg7) [108]. More directly, increased expression of autophagic
proteins (BNIP3, CTSS, ATG16L1) in human fibroblasts was sufficient to induce p21 up-
regulation and senescence, with a shift towards anaerobic glycolysis, lactate and 3-
hydroxybutirate production and a concomitant increase in in vivo tumor enhancing
properties [6]. The specific mechanisms linking autophagy to senescence and the SASP are
still unclear, but alterations in protein turnover and/or intracellular membrane trafficking are
likely involved [108]. A converse link is also possible, whereby senescence of stromal cells
induces autophagy. In particular, the expression of cyclin dependent kinase inhibitors (p16,
p19 or p21) in immortalized human fibroblasts triggered autophagy, and this "senescence-
induced" autophagy enhanced the growth of neighboring tumor cells in vivo [109]. This
could be mediated by autophagy-based unconventional secretion, termed "autosecretion",
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which enables leaderless cytosolic proteins including important cytokines of the SASP
(IL-1β, IL-18) to exit the cell without entering the secretory pathway [110].
A novel process called senescence-autophagy transition (SAT) [6] may also occur. During
SAT, senescent stromal cells promote epithelial cell growth in the absence of a SASP, by
releasing catabolic high energy "mitochondrial fuels” generated as a consequence of a
cellular glycolytic switch [6]. In this context, autophagy can be part of a vicious cycle
between stromal cells and cancer cells, involving a two-compartment tumor metabolism.
Cancer cells, by producing ROS, would stimulate autophagy in the surrounding stroma and
this autophagy-dependent senescence of stromal cells in turn would produce high-energy
catabolites that fuel back to the adjacent cancer cells (Figure 2) [6, 111]. Consistent with this
“reverse Warburg effect”, evidence for a stromal-epithelial lactate metabolic coupling was
found in breast cancer - CAFs expressed the transporter implicated in lactate efflux mono-
carboxylase (MCT) 4, while adjacent cancer cells expressed the transporter involved in
lactate influx MCT-1 [112].
Concluding remarks
As we have discussed, both stromal cell senescence and chronic inflammation have a
demonstrated tumor initiating function, with an ensuing reciprocal reinforcement of tumor
and stromal alterations (Figure 1). The use of anti-inflammatory agents, specifically COX
inhibitors, for prevention of cancer is already strongly supported by a number of
experimental and clinical studies [21, 22]. However, given the intrinsic fail safe function
that cellular senescence fulfills to restrict cancer cells of origin, the ability to interfere with
this process is much more complicated. More specific approaches should be considered such
as selectively inhibiting senescence and associated SASP/CAF activation in the stromal
mesenchyme while, at the same time, not interfering or enhancing senescence in
neighboring cancer precursor cells. Selective targeting of the stroma will be achieved by a
better knowledge of the tissue-specific mechanisms at the basis of the senescence program,
or use of better, tissue-specific drug delivery approaches, including recently developed
multiple needle microinjection techniques [113].
Autophagy is a similar dual edge sword. On one hand, overall enhancement of this process,
which can result from caloric restrictions or drugs with similar metabolism-modulatory
effects (like metformin or resveratrol), could be beneficial in preventing the overall tissue
and organismal aging process (Figure 3A). On the other hand, inhibition of autophagy at
both cancer and cancer stromal levels could have very favorable effects in suppressing
cellular senescence and associated events like, most prominently, inflammation (Figure 3B).
It is hard to predict a priori which of the two functions is predominant. Experiments in cell
culture are likely to skew conclusions in favor of the second possibility, while the ultimate,
and biologically most relevant tests, will have to be in vivo, especially under conditions in
which organ and organismal aging can be taken into consideration. Collectively, alterations
of the underlying stroma make it an attractive target for preventive and therapeutic
approaches against tumor initiation. In addition, such targets may also be highly beneficial
for later stages of epithelial cancer, i.e. invasion and metastasis, in which stromal changes
are known to play a critical role [10].
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BOX1: RESIDENT STROMAL CELLS
Substantial similarities exist in the stromal compartment of various organs, including the
bone marrow [114]. Besides providing basic physical support, stromal cells play an
essential function in development and organogenesis, contributing to tissue repair and
disease development [115]. The stroma is composed of a complex and loosely organized
network of multiple cell types embedded in an extracellular matrix that provides
structural support and participates in the control of cellular signaling. The stroma is
composed of the following major cell types: fibroblasts, pericytes, smooth muscle and
endothelial cells, pre-adipocytes, and mesenchymal stem cells.
Fibroblasts share a commonality of function, i.e. extracellular matrix production for
tissue maintenance and repair, but can have heterogeneous properties even within the
same organs, that can be maintained with cultivation [116, 117]. These cells are key in
orchestrating stromal composition and contribute to tissue repair through several
mechanisms including conversion into contractile myofibroblasts [42].
Pericytes, smooth muscle and endothelial cells are stromal components which play a role
in angiogenesis. While pro-angiogenic cytokines are produced by epithelial and stromal
cells at early cancer stages or as a consequence of inflammation [10], increased
angiogenesis is usually considered a late event in carcinogenesis [10].
While generally assumed to be confined to adipose tissue, pre-adipocytes can also be
found in the bone marrow [118] and stromal compartments of other organs such as skin
[119]. A possible involvement of these cells in carcinogenesis has not been assessed, but
it seems likely in view of their involvement during wound healing [119]. There are also
interesting similarities between the gene expression program of pre-adipocytes and
macrophages with the first cell type having the potential of converting into the other
[120, 121]. A functional interconnection also exists between mesenchymal stroma and
underlying adipose tissue, which can be a source of mesenchymal stem cells as well as
cytokines triggering stromal cell senescence and/or inflammation [122].
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BOX2: THE CONNECTION BETWEEN CANCER ASSOCIATED
FIBROBLASTS AND WOUND HEALING
Many similarities exist between cancer associated tissue alterations and acute wound
healing, including a common gene expression signature of surrounding fibroblasts [8].
Cancer has been defined as a "wound that never heals" [7] and wound healing can
promote cancer formation [123]. In the skin, the wound healing reaction is associated
with the conversion of stromal fibroblasts into contractile myofibroblasts, which, upon
successful healing, normally disappear as a consequence of cytokine -induced apoptosis
(e.g.IL1, TGF-ß) or senescence [42]. Cancer Associated Fibroblasts (CAFs) can be
viewed as myofibroblasts that persist under pathological conditions [9], and α-smooth
muscle actin (α-SMA) is a common marker used for the identification of both
myofibroblasts and CAFs. Importantly, however, α-SMA is expressed only in CAFs of
certain cancer types [124, 125], consistent with organ specific differences of resident
fibroblast populations. As a general definition, CAFs consists of fibroblasts capable of
enhancing tumorigenic behavior of neighboring epithelial cells [9, 10]. As discussed,
these cells may not only promote but initiate epithelial cancer.
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Highlights
- Stromal compartment can be a primary determinant of early stages of
epithelial cancer
- Stromal cellular environment can be responsible for recurring cancers
- Senescence and senescence associated secretory phenotype can create a
permissive stromal environment
- Tissue chronic inflammation and deregulated autophagy in the stroma can
contribute in promoting neoplastic transformation
- The selective targeting of these processes at stromal level might represent an
alternative approach in cancer prevention and therapy
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Figure 1. Determining the role of stromal cell senescence and inflammation in initiation of
epithelial carcinogenesis
(A) Surface epithelial tissues like those of the bronchial tree, bladder or skin are exposed to
and protected from environmental stressors and carcinogens like smoke, kidney-secreted
toxic chemicals, γ-irradiation and UV light. Pro-oncogenic gene mutations induced by these
agents are however not sufficient to elicit the carcinogenic process with senescence of
oncogene-bearing epithelial cells as a counteracting induced mechanism. The impact of
environmental stressors extends however to the underlying stroma, with induction of stromal
cell senescence and recruitment of a chronic inflammatory infiltrate as consequences that
reinforce each other. (B) Fibroblast senescence produces large amounts of diffusible growth
factors, cytokines, and matrix remodeling enzymes (SASP). In addition, chronic
inflammation (with prevalent M2 macrophages and Th1 T cells) generates highly reactive
small molecular weight molecules (ROS, RNS). Collectively, these factors impinge on the
overlying epithelium, with mitogenic and chromosome-destabilizing effects, thus promoting
tumorigenic outgrowth. As discussed in this review, an emerging concept is that approaches
aimed at suppressing stromal cell senescence and chronic inflammation could be of
substantial value for preventing or reversing early stages of epithelial cancer.
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Figure 2. Metabolic crosstalk between epithelial cancer cells and surrounding stroma
Proposed existence of a two-compartment tumor metabolism whereby epithelial cancer
cells, via reactive oxygen species (ROS) and ammonia, released as by-product of
preferential glutamine use, stimulate stromal cell autophagy, mitophagy (a form of
autophagy targeting selectively the mitochondria) and subsequent glycolysis. Autophagy can
lead to a senescent phenotype in stromal fibroblasts, with senescence-dependent or -
independent production of various SASP components. In addition, changes in metabolism of
stromal cells result in release of high-energy catabolites (e.g. lactate) that fuel-back to the
cancer cells (reverse Warburg effect) [6]. As discussed in the text, autosecretion, an
autophagy-based unconventional secretion enabling leaderless cytokines to exit the cell
without entering the secretory pathway, might contribute to modifying this stromal
environment.
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Figure 3. Complex interplay of aging, senescence and autophagy in stromal cell alterations and
epithelial cancer initiation
Aging can lead to senescence of stromal cells in parallel with CAF activation, chronic
inflammation and increased MMP production with matrix remodeling. As discussed in the
text, the NF-κB, AP1, Nrf2 and Notch/CSL signaling pathways have been implicated in one
or more of these processes. Autophagy can delay or limit the negative consequences of
tissue / organismal aging (A) while, at the same time, playing a more direct positive role in
stromal cell senescence (B). Senescence of stromal cells is linked to CAF activation and
chronic inflammation, while, in epithelial cells, it functions in concert with differentiation as
intrinsic tumor suppressing mechanism.
Goruppi and Dotto Page 20
Trends Cell Biol. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Goruppi and Dotto Page 21
Table 1
Molecular targets and pharmacologic modulators for cellular microenvironment
Signaling Pathway/
Molecular Target Agent(s) Effect on target
Cancer cell type involved
(in vivo or cell line)
INFLAMMATION
NFKB N-acetyl cysteine, Resveratrol, Sutinib Inhibitory [1–3] RCC, GIST [4, 5]
COX1/2 Celecoxib, Aspirin, other NSAIDs Inhibitory [6, 7] Colon polyp recurrence, Breast,
Oesophageal, Gastric, Biliary [8, 9]
NOS L-NAME Inhibitory [10] Breast [10]
AP1 signaling PYC71N, JIP peptide, Resveratrol Inhibitory [2, 11, 12] Breast [13]
NRF2 Sulphoraphane, Dimethyl fumarate Activation [14] Prostate [15]
NRF2 Brusatol Inhibitory [16] Lung [16]
MMPs Marimastat, MMP3 inhibitor peptide Inhibitory [17, 18] Lung, Colon [17, 19]
TGF β signaling AP12009, LY 364947, SB 525334 Inhibitory [20–22] Prostate, Glioma [23, 24]
SENESCENCE
Notch/CSL SAHM1, MK0752, RO4949079 Inhibitory [25, 26] Breast, Prostate [24, 27]
p21 Senexin A Inhibitory [28] Adenocarcinoma [28]
MEK Trametenib, PD035901, UO126, Pimasertib Inhibitory [29–31] Melanoma, Lung, Colon [32–34]
AUTOPHAGY
mTORC complex Rapamycin, Torin, CCI-779, RAD001,
AP23573
Activation [30, 35] Glioma, Prostate, RCC [24, 36, 37]
AMPK Metformin, AICAR, A-769662 Activation [30, 38] Breast, Colon [39, 40]
BH3 ABT 737, GX15-070 Activation [41, 42] Pancreas, Leukemia [43, 44]
HDAC Sperimidine, Apicidin, SAHA,
Sulphoraphane
Activation [14, 45, 46] Breast, CML [47–49]
Autophagosome/ly sosome Bafilomycin A1, Chloroquine Inhibitory [50, 51] Breast, Prostate, Glioma [47, 52, 53]
Vps34, PI3Kγ 3-methyl-adenine Inhibitory [50, 51] Colon, Breast [54, 55]
• This Table indicates potential molecules that might be targeted in the stroma for cancer preventive-therapeutic purposes as well as some type of
cancers or cell lines where certain indicated drugs have been found to be effective, and is not meant to be a comprehensive list of inhibitors/
activators.
• Note that some agents directly target the indicated molecules while others act modulating the pathway leading to the molecular target.
List of abbreviation used:
EGCG (epigallocatechin-3-gallate); Celecoxib (sulfonamide nonsteroidal anti-inflammatory drug, NSAID); NSAIDs (non-steroidal anti-
inflammatory drugs); AICAR (5-amino-1-β-ribofuranosylimidazole-4-carboxamide); Vps34 (phosphatylinositol 3-kinase class III); PI3Kγ
(phosphoinositide 3-kinase gamma ); Senexin A (inhibitors of p21-dependent transcription); Resveratrol (3,5,4'-trihydroxy-trans-stilbene);
Sutinib (targets multiple receptor tyrosine kinases. Including all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial
growth factor receptors); L-NAME (N-nitro-L-arginine methyl ester); Sulphoraphane (1-Isothiocyanato-4-methylsulfinylbutane, polyvalent
molecule derived from vegetables, activates NRF2); SAHM1 (hydrocarbon-stapled peptides that disrupt a critical protein-protein interaction in the
Notch/CSL transcription factor complex); Marimastat (BB2516, broad spectrum MMP inhibitor); Torin (mTOR kinase activity inhibitor);
CCI-779, RAD001 and AP23573 (mTOR inhibitors analog to rapamycin); Brusatol (selectively inhibits NRF2 ); JIP (Jun interacting protein1);
MMP3 inhibitor I (Ac-Arg-Cys-Gly-Val-Pro-Asp); Spermidine (polyamine compound, HDAC inhibitor)
COX2 (cyclooxygenase 2); TGFβ (transforming growth factor-β); mTOR (mammalian target of rapamycin); AMPK (AMP activated kinase);
MEK (mitogen-activated protein kinase); MMPs (metalloproteinase); AP1 (activating complex protein 1); NFκB (nuclear factor κB); HDAC
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(histone deacetylase); KEAP1 (kelch-like ECH-associated protein 1); p21 (cyclin dependent inhibitor waf1); HDAC (Histone deacetylases ); BH3
(bcl2 homology domain 3); CML (chronic myeloid leukemia); RCC (renal cell carcinoma); GIST (gastrointestinal stromal tumors)
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